Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Test the maximum tolerated dose (MTD) of Bendamustine with whole brain radiation therapy
(WBRT)
- To determine the plasma pharmacokinetics (a blood test to see how much of the drug is
getting into the patient's system and how long it lasts in the system) of Bendamustine
- To determine the presence of Bendamustine in cerebrospinal fluid (CSF) (fluid from the
brain and spinal cord) of study patients Bendamustine is approved by the Food and Drug
Administration (FDA) for chronic lymphocytic leukemia. However, Bendamustine will be
used in this study as an investigational agent.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute